IsoBlog

PSMA-11: The Gold Standard in Prostate Cancer Imaging

Read More »

November 5, 2024

Unveiling the Significance of SUV Measure in Theranostics

Read More »

May 9, 2024

Nuclear Medicine role in Neuroendocrine Tumors

Read More »

January 17, 2024

Terbium 161 for Targeted Radionuclide Therapy in Oncology

Read More »

October 15, 2023

Terbium-161 Radionuclide Therapy in Prostate Cancer

Read More »

October 15, 2023

Radiopharmacy and Radiobiology Aspects for 161-Terbium

Read More »

October 10, 2023

The Future of Theranostics in Prostate Cancer- PSMA RLT and Combination Therapy

Read More »

August 21, 2023

Is there a future for PSMA theranostics in Osteosarcoma?

Read More »

March 16, 2023

PSMA theranostics in tumors other than prostate cancer

Read More »

December 25, 2022

Nuclear imaging in Parkinson’s disease- The past, the present, and the future

Read More »

May 16, 2022

Overcoming Lutetium-177 Production and Supply Challenges

Read More »

April 21, 2022

Vision study – Research on Prostate Cancer

Read More »

April 16, 2020

proPSMA study

Read More »

April 6, 2020

18F-DOPA use in Parkinsonism

Read More »

February 16, 2020

Lutetium 177 production (Lu177 production)

Read More »

February 10, 2020

PERSONALIZED NUCLEAR MOLECULAR CANCER THERAPY

Read More »

February 3, 2020

Prostate cancer

Read More »

February 3, 2020